Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
Johnson & Johnson(JNJ) stock is priced at $237.26, giving the company a market capitalization of 571.72B. It carries a P/E multiple of 21.51 and pays a dividend yield of 2.2%.
On 2026-03-19, Johnson & Johnson(JNJ) shares started trading at $237.90, with intraday highs of — and lows of —.
Trading volume for Johnson & Johnson(JNJ) stock has reached 776, versus its average volume of 7.43M.
The stock's 52-week range extends from a low of $141.50 to a high of $251.71.
The stock's 52-week range extends from a low of $141.50 to a high of $251.71.
JNJ News
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for moderate-to-severe p...
Barclays raised the firm’s price target on Johnson & Johnson to $234 from $217 and keeps an Equal Weight rating on the shares. The firm says its analysis confir...
On 18 March 2026, Johnson & Johnson received U.S. FDA approval for ICOTYDE (icotrokinra), the first targeted oral IL-23 receptor antagonist for moderate-to-seve...
Analyst ratings
59%
of 29 ratingsMore JNJ News
Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling sh...
Protagonist Therapeutics (PTGX) announced that Johnson & Johnson (JNJ) received FDA approval for ICOTYDE, or icotrokinra, an interleukin-23 receptor antagonist...
Johnson & Johnson (JNJ) on Wednesday announced that the U.S. Food and Drug Administration (FDA) approved Icotyde, a once-daily pill developed with Protagonist T...
Johnson & Johnson announced that the U.S. Food and Drug Administration, FDA, has approved Icotyde, an interleukin-23 receptor antagonist for the treatment of mo...
Johnson & Johnson (JNJ) is back in focus after recent trading, with the stock closing at US$238.11. Investors are weighing this move against its month and past...
A California judge has overturned a jury’s decision ordering Johnson & Johnson to pay nearly $1B in punitive damages to the family of a woman who died from meso...
In early trading on Tuesday, shares of Goldman Sachs Group topped the list of the day's best performing Dow Jones Industrial Average components, trading up 2.8%...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.